Beijing Continent Pharmaceutical Co, Ltd.

This study is testing the safety of a higher dose of hydronidone capsules in people with liver scarring (fibrosis) and cirrhosis caused by chronic hepatitis B. 300 adult participants will take the capsules for 28 days and be monitored for side effects. The goal is to gather safet…

This study is testing whether a drug called pirfenidone can help people who develop lung injury after radiation therapy for cancer, sometimes combined with immunotherapy. About 298 adults with mild to moderate lung damage will take either pirfenidone or a placebo (inactive pill) …

This large, 5-year study aims to see if adding the drug Hydronidone to standard antiviral therapy can prevent serious liver complications in people with chronic hepatitis B who already have liver scarring (fibrosis). It will involve about 1,200 adults and compare Hydronidone agai…

This study is testing the safety of an experimental capsule called hydronidone in people with liver fibrosis (scarring) caused by chronic hepatitis B or fatty liver disease. About 200 participants will take the capsules three times a day for 28 days. The main goal is to see what …

This study is testing the safety of a new oral medication called Hydronidone in people with liver scarring caused by chronic hepatitis B. The main goal is to see how well the drug is tolerated and to check for side effects. All 150 participants will take the drug for 28 days whil…

This is an early-stage study to understand how a new drug capsule called Hydronidone moves through the body. It will test the drug's safety and how it is processed in 138 healthy volunteers. The goal is to gather information to support future studies in people with liver fibrosis…

This early-stage study aims to check if a single dose of an experimental drug called Hydronidone is safe for the heart. The drug is being developed to treat liver scarring (fibrosis). Researchers will give the drug to 48 healthy Chinese volunteers and closely monitor their heart …

This is an early, small study to understand how the body processes a drug called Hydronidone, which is being developed for liver scarring from hepatitis B. Eight healthy Chinese men will receive a single dose containing a tiny, safe amount of radioactive tracer. Researchers will …

This early study aims to understand how a new drug for liver scarring (hydronidone) interacts with four common hepatitis B medications when taken together. Researchers will measure drug levels in the blood of 64 healthy Chinese volunteers to see if the drugs affect each other. Th…

This is an early safety study to understand how a new drug for liver fibrosis, called hydronidone, is processed by the body in people with different levels of liver damage. It will enroll 30 people, including those with mild to moderate liver impairment and others with healthy li…